Protalix BioTherapeutics (PLX) Capital Expenditures (2010 - 2026)
Protalix BioTherapeutics' (PLX) quarterly Capital Expenditures came in at $761000.0 in Q1 2026, up 78.22% year-on-year from $427000.0 in Q1 2025, and up 187.88% quarter-over-quarter from -$866000.0 in Q4 2025.
Protalix BioTherapeutics (PLX) Capital Expenditures (2010 - 2026) Analysis & Trends
Protalix BioTherapeutics' Capital Expenditures history runs 17 years deep, the most recent figure standing at $761000.0 for Q1 2026.
- On a quarterly basis, Capital Expenditures rose 78.22% year-over-year to $761000.0 in Q1 2026; TTM through Mar 2026 was $703000.0, a 55.02% decrease from a year earlier, with the FY2025 full-year figure at $369000.0, down 71.22% from the prior year.
- Capital Expenditures rose to $761000.0 in Q1 2026 per PLX's latest filing, from -$866000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $857000.0 in Q3 2025 and bottomed at -$866000.0 in Q4 2025.
- The 5-year median for Capital Expenditures is $126000.0 (2023), against an average of $186411.8.
- Biggest YoY gain for Capital Expenditures was 800.0% in 2023; the steepest drop was 359.68% in 2023.
- Year by year, Capital Expenditures stood at -$62000.0 in 2022, then sank by 359.68% to -$285000.0 in 2023, then jumped by 249.12% to $425000.0 in 2024, then tumbled by 303.76% to -$866000.0 in 2025, then surged by 187.88% to $761000.0 in 2026.
- Per Business Quant, the three latest PLX Capital Expenditures figures stand at $761000.0 (Q1 2026), -$866000.0 (Q4 2025), and $857000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Protalix BioTherapeutics | 190.95 Mn | 180.16 Mn | 29.62 Mn | 761,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 761,000.00 |
| Mar 31, 2026 | 761,000.00 |
| Dec 31, 2025 | -866,000.00 |
| Dec 31, 2025 | -866,000.00 |
| Sep 30, 2025 | 857,000.00 |
| Sep 30, 2025 | 857,000.00 |
| Jun 30, 2025 | -49,000.00 |
| Jun 30, 2025 | -49,000.00 |
| Mar 31, 2025 | 427,000.00 |
| Mar 31, 2025 | 427,000.00 |
| Dec 31, 2024 | 425,000.00 |
| Dec 31, 2024 | 425,000.00 |
| Sep 30, 2024 | 736,000.00 |
| Sep 30, 2024 | 736,000.00 |
| Jun 30, 2024 | -25,000.00 |
| Jun 30, 2024 | -25,000.00 |
| Mar 31, 2024 | 146,000.00 |
| Mar 31, 2024 | 146,000.00 |
| Dec 31, 2023 | -285,000.00 |
| Dec 31, 2023 | -285,000.00 |